[Federal Register: August 6, 2008 (Volume 73, Number 152)]
[Notices]
[Page 45785-45786]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr06au08-97]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on June 27, 2008, Cody
Laboratories, 601 Yellowstone Avenue, Cody, Wyoming 82414, made
application by renewal to the Drug Enforcement Administration (DEA) as
a bulk manufacturer of the basic classes of controlled substances
listed in schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Dihydromorphine (9145)..................... I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Amobarbital (2125)......................... II
Pentobarbital (2270)....................... II
Secobarbital (2315)........................ II
Phenylacetone (8501)....................... II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
Oxycodone (9143)........................... II
[[Page 45786]]
Hydromorphone (9150)....................... II
Diphenoxylate (9170)....................... II
Ecgonine (9180)............................ II
Hydrocodone (9193)......................... II
Meperidine (9230).......................... II
Methadone (9250)........................... II
Morphine (9300)............................ II
Oxymorphone (9652)......................... II
Alfentanil (9737).......................... II
Remifentanil (9739)........................ II
Sufentanil (9740).......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans on manufacturing the listed controlled substances
in bulk for sale to its customers.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than October 6, 2008.
Dated: July 30, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E8-18047 Filed 8-5-08; 8:45 am]
BILLING CODE 4410-09-P